Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic
Nutrients · 2024
DOI: 10.3390/nu16152568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Joanna Smyczyńska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, 90-419 Lodz, Poland. Hauptthemen laut MEDLINE: COVID-19, Blood Glucose, Prediabetic State, Pediatric Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Childhood obesity, with its metabolic complications, is a problem of public health. The International Diabetes Federation (IDF) has recommended glucose levels 1 h post oral glucose load (1h-PG) > 155–209 mg/dL as diagnostic for intermediate hyperglycemia (IH), while >209 mg/dL for type 2 diabetes (T2D). The aim of the study was to assess the occurrence of prediabetes, IH, and T2D in children and adolescents with simple obesity according to the criteria of American Diabetes Association (ADA) and of IDF, and the effect of COVID-19 pandemic on these disorders. Analysis included 263 children with simple obesity, screened either in prepandemic (PRE—113 cases) or post-pandemic period (POST—150 cases). All children underwent 2 h OGTT with measurements of glucose and insulin every 0.5 h, lipid profile, and other tests; indices if insulin resistance (IR): HOMA, QUICKI, Matsuda index, AUC (glu/ins) were calculated. The incidence of T2D, prediabetes, and IH was higher in POST with respect to PRE, with significant differences in the indices of IR, except for HOMA. Significant differences were observed in the assessed parameters of glucose metabolism among the groups with T2D, prediabetes, IH, and normal glucose tolerance (NGT), with some similarities between IH (based on 1h-PG) and prediabetes. Increased frequency of dysglycemia among children and adolescents with simple obesity is observed after COVID-19 pandemic. Metabolic profile of patients with IH at 1h-PG is “intermediate” between NGT and prediabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, 90-419 Lodz, Poland.
- Department of Pediatrics, Endocrinology, Diabetology and Nephrology, Central Clinical Hospital of Medical University of Lodz, 90-419 Lodz, Poland.
- Outpatient Clinic of Diabetology, Central Clinical Hospital of Medical University of Lodz, 90-419 Lodz, Poland.
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-401 Lodz, Poland.
ORCID-Profile: Joanna Smyczyńska, Urszula Smyczyńska, Beata Mianowska
Zitieren
APA
Smyczyńska, J., Olejniczak, A., Różycka, P., Chylińska-Frątczak, A., Michalak, A., Smyczyńska, U., Mianowska, B., Pietrzak, I., & Szadkowska, A. (2024). Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic. Nutrients. https://doi.org/10.3390/nu16152568
Vancouver
Smyczyńska J, Olejniczak A, Różycka P, Chylińska-Frątczak A, Michalak A, Smyczyńska U, et al. Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic. Nutrients. 2024. doi:10.3390/nu16152568
BibTeX
@article{Smyczyska2024,
author = {Smyczyńska, Joanna and Olejniczak, Aleksandra and Różycka, Paulina and Chylińska-Frątczak, Aneta and Michalak, Arkadiusz and Smyczyńska, Urszula and Mianowska, Beata and Pietrzak, Iwona and Szadkowska, Agnieszka},
title = {Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16152568}
}
EUVIMED